Treating a Specific Lymphoma with Modified T Cells
This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.
Original patent title: “Chimeric antigen receptor T cell therapy”
This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient. Granted to Kite Pharma in 2026 with 10 claims, and it is expected to expire in 2040.
Coverage
What does this patent actually cover?
This patent outlines a method for treating relapsed or refractory mantle cell lymphoma (MCL) in patients who have specific tumor characteristics, either a Ki-67 tumor proliferation index of 50% or higher, or a TP53 gene mutation (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). The treatment involves collecting a patient's own (autologous) T cells from their blood, enriching them for specific types (CD4+ and CD8+), and removing any circulating cancer cells (Claim 1). These T cells are then engineered to express a "chimeric antigen receptor" (CAR) that specifically targets a protein called CD19, using a particular anti-CD19 component called FMC63 (Claim 1). Before receiving these modified T cells, patients may get a "bridging therapy" and a "lymphodepleting chemotherapy" to prepare their body (ClaimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → 5, 7).
The gap
What does this patent NOT cover?
- Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR T cell therapies that use T cells from a donor (allogeneic) rather than the patient's own (autologous) cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR T cells designed to target cancer markers other than CD19, or those using a different anti-CD19 component than the FMC63 single-chain variable fragment (scFv) (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR T cells prepared without the specific steps of positive enrichment and partial or complete depletion of circulating cancer cells from peripheral blood mononuclear cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
- Does not cover CAR T cells that use different intracellular signaling regions than the specified CD28 and CD3-zeta domains (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The noveltynoveltyThe requirement that an invention be different from anything publicly known before its priority date.Read more → lies in precisely defining the patient population (relapsed/refractory MCL with specific genetic markers) and the exact CAR T cell construct and preparation method (autologous, anti-CD19 FMC63 scFv, CD28/CD3-zeta signaling, specific enrichment/depletion) to improve outcomes for these challenging cases.
The Patent Drawing
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Yescarta (axicabtagene ciloleucel, developed by Kite Pharma/Gilead Sciences)
Other CD19-targeted CAR T cell therapies for lymphoma
Clinical trials for CAR T cell therapies in relapsed/refractory MCL
Why it matters
The bigger picture
Mantle cell lymphoma (MCL) is an aggressive blood cancer that is often difficult to treat, especially after initial therapies fail. This patent focuses on a specific, challenging subset of MCL patients, offering a new approach using genetically engineered T cells. Kite Pharma, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is a major player in the CAR T cell therapy field, having developed one of the first approved CAR T cell treatments. This patent aims to refine and expand the application of this powerful technology for a critical patient population.
Filed
November 6, 2020
Granted
April 14, 2026
Market context
Who's building on this
Companies in this space
Kite Pharma, now part of Gilead Sciences, is a leader in CAR T cell therapy and continues to develop and commercialize treatments like Yescarta. Other major pharmaceutical companies such as Novartis (Kymriah) and Bristol Myers Squibb (Breyanzi, Abecma) are also actively developing and expanding their CAR T cell portfolios for various blood cancers. Research institutions and biotech startups are continually exploring new CAR designs and targets.
Market impact
CAR T cell therapy has created a new category of "living drugs" for certain blood cancers, offering hope for patients with limited options. This patent contributes to the ongoing expansion and refinement of CAR T applications, specifically targeting a difficult-to-treat subtype of MCL. Such advancements can lead to new product approvals, expand the addressable patient population for existing therapies, and drive further investment and innovation in the cell therapy market, potentially influencing clinical practice guidelines for lymphoma treatment.
Claim 1 — Plain English
What this patent covers
This patent outlines a method for treating relapsed or refractory mantle cell lymphoma (MCL) in patients who have specific tumor characteristics, either a Ki-67 tumor proliferation index of 50% or higher, or a TP53 gene mutation (Claim 1). The treatment involves collecting a patient's own (autologous) T cells from their blood, enriching them for specific types (CD4+ and CD8+), and removing any circulating cancer cells (Claim 1). These T cells are then engineered to express a "chimeric antigen receptor" (CAR) that specifically targets a protein called CD19, using a particular anti-CD19 component called FMC63 (Claim 1). Before receiving these modified T cells, patients may get a "bridging therapy" and a "lymphodepleting chemotherapy" to prepare their body (Claims 5, 7).
The clever bit
The novelty lies in precisely defining the patient population (relapsed/refractory MCL with specific genetic markers) and the exact CAR T cell construct and preparation method (autologous, anti-CD19 FMC63 scFv, CD28/CD3-zeta signaling, specific enrichment/depletion) to improve outcomes for these challenging cases.
What it does not cover
- Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1).
- Does not cover CAR T cell therapies that use T cells from a donor (allogeneic) rather than the patient's own (autologous) cells (Claim 1).
- Does not cover CAR T cells designed to target cancer markers other than CD19, or those using a different anti-CD19 component than the FMC63 single-chain variable fragment (scFv) (Claim 1).
- Does not cover CAR T cells prepared without the specific steps of positive enrichment and partial or complete depletion of circulating cancer cells from peripheral blood mononuclear cells (Claim 1).
- Does not cover CAR T cells that use different intracellular signaling regions than the specified CD28 and CD3-zeta domains (Claim 1).
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
7/20
Moderate scope
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$68K – $216K
Midpoint $135K · 14.2 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
10 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Rossi, J., & Bot, A. (2026). Treating a Specific Lymphoma with Modified T Cells (U.S. Patent No. 12,600,775). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12600775"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 9328156 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Attack Cancer
US 9481728 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Fight CD19 Cancers
US 20240165159 · Purdue Research Foundation
Targeting Cancer with CAR T Cells Using a Chemical Tag
US 20250171803 · Purdue Research Foundation
Targeting Cancer with CAR T Cells Using Small Molecule 'Flags'
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Treating a Specific Lymphoma with Modified T Cells cover?
This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.
Who owns patent US 12600775?
Kite Pharma owns this patent, granted in 2026.
When does this patent expire?
This patent is expected to expire on November 6, 2040, when the invention enters the public domain.
What problem does this patent solve?
Mantle cell lymphoma (MCL) is an aggressive blood cancer that is often difficult to treat, especially after initial therapies fail. This patent focuses on a specific, challenging subset of MCL patients, offering a new approach using genetically engineered T cells. Kite Pharma, the assignee, is a major player in the CAR T cell therapy field, having developed one of the first approved CAR T cell treatments. This patent aims to refine and expand the application of this powerful technology for a critical patient population.
What does this patent NOT cover?
Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1).
Patent monitoring